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Abstract
Background: Recent evidence has underscored the role of hypoxia and angiogenesis in the pathogenesis of idiopathic
fibrotic lung disease. Inhibitor of growth family member 4 (ING4) has recently attracted much attention as a tumor
suppressor gene, due to its ability to inhibit cancer cell proliferation, migration and angiogenesis. The aim of our study
was to investigate the role of ING4 in the pathogenesis of pulmonary fibrosis both in the bleomycin (BLM)-model and in
two different types of human pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF) and cryptogenic organizing
pneumonia (COP).
Methods: Experimental model of pulmonary fibrosis was induced by a single tail vein injection of bleomycin in 6- to 8-
wk-old C57BL/6mice. Tissue microarrays coupled with qRT-PCR and immunohistochemistry were applied in whole lung
samples and paraffin-embedded tissue sections of 30 patients with IPF, 20 with COP and 20 control subjects.
Results: A gradual decline of ING4 expression in both mRNA and protein levels was reported in the BLM-model. ING4
was also found down-regulated in IPF patients compared to COP and control subjects. Immunolocalization analyses
revealed increased expression in areas of normal epithelium and in alveolar epithelium surrounding Masson bodies, in
COP lung, whereas showed no expression within areas of active fibrosis within IPF and COP lung. In addition, ING4
expression levels were negatively correlated with pulmonary function parameters in IPF patients.
Conclusion: Our data suggest a potential role for ING4 in lung fibrogenesis. ING4 down-regulation may facilitate
aberrant vascular remodelling and fibroblast proliferation and migration leading to progressive disease.
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Introduction
Idiopathic interstitial pneumonias (IIPs) are a heteroge-
neous group of diffuse parenchymal diseases comprising
of seven distinct clinical and pathological entities[1].
Among others idiopathic pulmonary fibrosis (IPF) and
cryptogenic organizing pneumonia (COP) represent two
of the most prevalent members of the disease group with
major differences in pathogenesis, clinical course and
prognosis. IPF is a refractory and lethal IIP characterized
by fibroblast proliferation, extracellular matrix deposition
and progressive lung scarring, comprising the histopatho-
logic pattern of usual interstitial pneumonia (UIP)[2].
The incidence of IPF is estimated at 15–40 cases per
100,000 per year, and the mean survival from the time of
diagnosis is 3–5 yr regardless of treatment [3]. Despite
intense research efforts, their aetiopathogenesis is still elu-
sive and controversial and consequently their treatment
ineffective [4-6].
Inhibitor of growth family member 4 (ING4) languished
in relative obscurity until the past three years when it
emerged to function as a tumor suppressor gene, repress-
ing cell proliferation[7], tumor growth[8], loss of contact
inhibition [8-10] and angiogenesis[10]. ING4 belongs to
a family of proteins comprising six members character-
ized by a highly conserved C-terminal plant homedomain
(PHD)-like zinc-finger domain and has been implicated
in a variety of processes including oncogenesis, apoptosis,
DNA repair and cell cycle control[11]. Although, its pre-
cise mechanism of action has yet to be elucidated, ING4
seems to inhibit angiogenesis through interaction with
hypoxia inducible factor (HIF) proly hydroxylases
(HPH)[12,13] and RelA subunit of NF-Kβ [14]resulting in
downregulation of HIF activation[12,13] and repression
of angiogenesis related genes including IL6, IL-8 and
Cox2[14], respectively. We have recently performed com-
parative expression profiling of disease progression in a
well characterized animal model of pulmonary fibrosis
and produced a number of highly involved genes in the
disease pathogenesis. Among them, the role of HIF-1a sig-
naling was further investigated and revealed overexpres-
sion of HIF-1a in the alveolar epithelium, both in the
bleomycin-model and human pulmonary fibrosis sug-
gesting a role in disease initiation and progression[15].
The aim of our study was to investigate the role of ING4
in the pathogenesis of pulmonary fibrosis by assessing its
expression both in the bleomycin (BLM)-model and in
two different types of human pulmonary fibrosis by using
tissue microarrays, quantitative reverse transcription -
(qRT)-polymerase chain reaction (PCR) and immunohis-
tochemistry. ING4 was found downregulated in both
mRNA and protein level within fibrotic lungs compared
to controls whereas a gradual decline of ING4 expression
following disease progression was noticed in the experi-
mental model of pulmonary fibrosis. The expression pat-
tern of ING4 within fibrotic lungs was inversely related
with that of HIF-1a, as has previously been demonstrated,
suggesting a role for this transcription factor during dis-
ease pathogenesis. Most intriguingly, ING4 semi-quanti-
tative expression levels were negatively correlated with
pulmonary function parameters in IPF patients, further
supporting the premise that ING4 could potentially serve
as a biomarker of disease progression.
Materials and methods
BLM-induced pulmonary inflammation and fibrosis
All mice strains were bred and maintained in the C57BL/
6 background for over 20 generations in the animal facil-
ities of the Biomedical Sciences Research Center "Alexan-
der Fleming" under specific pathogen-free conditions, in
compliance with the Declaration of Helsinki principles.
Mice were housed at 20–22°C, 55 ± 5% humidity, and a
12 h light-dark cycle; food and water was given ad libitum.
All experimentation was approved by an internal Institu-
tional Review Board, as well as by the veterinary service
and fishery department of the local governmental prefec-
ture. Pulmonary Fibrosis was induced by a single tail vein
injection of Bleomycin hydrogen chloride (100 mg/kg
body weight; 1/3 LD50; Nippon Kayaku Co. Ltd., Tokyo)
to 6- to 8-wk-old mice as previously reported in
detail[16].
Patients
In total, 50 newly diagnosed patients with IIPs of two dif-
ferent histopathologic patterns including 30 patients with
IPF/UIP and 20 with COP were recruited in our study. The
diagnosis was based on the consensus statement of the
ATS/ERS (2002)[1]. Paraffin-embedded surgical lung
specimens (open lung biopsy or by video assisted thora-
coscopic surgery-VATS) from two different fibrotic regions
of each individual were sampled. Approval by the local
ethical committee was obtained. Twenty control paraffin
blocks obtained from the normal part of lungs removed
for benign lesions were collected from the archives of the
Department of Pathology of three different institutions
(Table 1).
Quantitative Real-Time reverse transcriptase-polymerase 
chain reaction (qRT-PCR)
qRT-PCR was performed using the Chromo 4 Real-Time
Detection System and the Platinum® SYBR® Green qPCR
SuperMix-UDG (Invitrogen), according to the manufac-
turer's instructions. The program used included: 2 min at
50°C, 5 min at 95°C, 43 cycles of denaturation-anneal-
ing-extension (30s at 95°C; 45s at 56°C; 30s at 72°C) and
a final extension of 5 min at 72°C. Primers were chosen
from exons separated by large introns (spanning exon-
exon junctions), and the PCR quality and specificity was
verified by melting curve analysis and gel electrophoresis.Respiratory Research 2009, 10:14 http://respiratory-research.com/content/10/1/14
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Mouse (m) and human (h) primer sequences (s: sense, as:
antisense) and expected lengths (in bp) were as follows
(5' to 3'): (m) Ing4 (s: AAG GCC GGA CCC AAA AGG AG;
as: CCA ACA CAT CAG AGG GGT GG; 171 bp), (h) ING4
(s: AGC TTG CCA TGC AGA CCT; as: GCG CAC GAG CTT
TAA CTT; 245 bp). (m) B2m (s: TTC TGG TGC TTG TCT
CAC TGA; as: CAG TAT GTT CGG CTT CCC ATTC; 104
bp). (h) B2M  (s: CTG ACC CTA CAT TTT GTG CAT
AAAAG ATG AGT ATG CC; as: ACC CTA CAT TTT GTG
CAT AA; 202 bp). Cycle threshold (Ct; the first cycle that
amplification can be detected) values were obtained from
the Opticon monitor 3 software for each gene of interest
and the control reference gene, together with amplifica-
tion efficiencies (85–115%). Ct values were normalized to
the reference gene beta-2-microglobulin (B2m/B2M for
mouse and human respectively)[16].
For mouse samples the relative quantification method
was used. This method determines the changes in steady-
state mRNA levels of a gene of interest (GOI) across sam-
ples and expresses it relative to the levels of the control
sample (23c in this case). The relative quantification
Microsoft® Excel add-on macro (Bio-Rad Laboratories) that
utilizes the following mathematical model used to calcu-
late relative expression of GOI.
, where ΔCt =
CtGOI - CtReference. 5 mice per group/time point were uti-
lized (d7, d15, d23); 3 in the control group (d23c). Equi-
molar amounts of the mouse cDNAs from each group
were pooled together and were analyzed in triplicates. For
the human samples, Ct values of both the GOI-ING4 and
the reference gene B2M were converted to concentration
values (ng/ml) utilizing a standard curve made by serial
dilutions (in duplicates) of an arbitrary reference sample.
ING4  concentration values were divided to the corre-
sponding B2M values and presented as expression index.
Tissue microarray (TMA) construction
A total of 70 tissue samples consisting of 30 IPF and 20
COP lung specimens and 20 control tissues derived from
the normal part of lungs removed for benign lesions were
snap-frozen and stored at -70°C. Specimens were fixed in
cold-ethanol for 16 h and then embedded in paraffin.
Hematoxylin and eosin (H&E) -stained sections were
made from each block to define representative fibrotic
and inflammatory lesion regions. Areas of interest were
identified in H&E stained slides by a conventional micro-
scope (Olympus BX-50). Tissue cylinders with a diameter
of 1.5 mm were punched from selected areas of each
"donor" block using a thin-wall stainless tube from a pre-
cision instrument (TMA-100, Chemicon, USA) and were
transfered by a solid stainless stylet into defined array
coordinates in a 45 * 20 mm new recipient paraffin
block[17]. The tissue microarray blocks were constructed
in three copies (each containing one sample from a differ-
ent region of all lesions). One sample was taken from the
center and two samples from different peripheral areas.
Ultimately, we constructed two tissue microarray blocks
comprising of 100 tissue elements each. Each tissue ele-
ment in the array was 1.5 mm in diameter and spacing
between two adjacent elements was 0.1 mm. After the tis-
sue microarray construction 3 μm and 5 μm sections for
immunohistochemical analysis, respectively, were cut
from the "donor" blocks and were transferred to glass
slides using an adhesive-coated tap sectioning system.
Immunohistochemistry analysis
Immunohistochemistry for ING4 antigen was carried out
on using the anti-h-ING4 rabbit polyclonal unconjugated
antibody (10617-1-AP-Proteintech Group, Inc., Chicago,
IL, USA) and the anti-ING4 mouse polyclonal antibody
(Novus Biologicals Inc., Littleton, CO). The slides were
deparaffinized and En Vision immunohistochemistry
protocol (DAKO Corp, Denmark) was performed by the
use of an automated immunohistochemistry staining sys-
tem (Bond-Biogenex, USA). Diaminobenzidine (DAB)
was used as chromogenic substrate. This immunohisto-
chemistry protocol is based on a water-soluble, dextran
polymer system preventing the endogenous biotin reac-
tion, which is responsible for the background in the
stained slides. More specifically, the sections were incu-
bated with the primary antibody in "antibody diluent"
(DAKO) and goat-anti-mouse EnVision- HRP-enzyme
conjugate was performed for 3 min each. The "highly sen-
sitive 3,3,' diaminobenzidine plus" (DAB+) and the "3-
amino-9-ethylcarbazol plus" (AEC+) chromogens (both
from DAKO) were used as substrates for the EnVision-
HRP-enzymes. Staining intensity was further enhanced by
modifying the manufacturer's protocol in that all incuba-
tion steps (primary antibodies, EnVision, and substrate
reactions) were performed on slides placed horizontally
on a thermal plate at 37C. After each incubation, the
slides were dipped in TBS or, after the substrate reaction,
in tapwater at RT and waved at maximum speed for 10 sec.
Excess liquid (buffer/water) was soaked up by a paper
towel. Specimens of colon adenocarcinoma cases were
used as positive controls for the marker.
Evaluation of results by Computerized Image Analysis
In order to evaluate the immunohistochemistry results
not in a qualitative way but in a more accurate and relia-
ble way, we performed computerized image analysis by
using a semi-automated system (Matrox II Card Frame
Grabber, Camera Microwave Systems, Microscope Olym-
pus BX-50) allowing us to assess staining intensity in a
256 level scale – 0 (black)-255(white). Staining intensity
Relative expression
Ct Ct Sample control =
−− 2
() ΔΔRespiratory Research 2009, 10:14 http://respiratory-research.com/content/10/1/14
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values were then converted to reverse percentages {reverse
staining intensity = (1-staining intensity/256) ×100}
Statistical analysis
Statistical analysis was carried out using SPSS 14.0 soft-
ware. Results are expressed as mean ± SD, or median
(range), unless otherwise indicated. One way ANOVA was
used to compare reverse staining intensity values between
the three groups of subjects. In addition, statistical signif-
icance was further verified by performing independent
samples t-test to compare reverse staining intensity values
of ING4 between different forms of pulmonary fibrosis
and between patients and controls. Results were corrected
using Bonferroni correction. Spearman's correlation was
used to find relationship between pulmonary function
parameters and semi-quantitative expression levels of
ING4, in IPF patients. A p-value of < 0.05 was considered
as statistically significant.
Results
Decreased ING4 expression in the BLM model of 
pulmonary fibrosis following disease progression
As angiogenesis[15,18,19] and apoptosis[20,21] repre-
sent two of the major pathogenetic hallmarks of pulmo-
nary fibrosis and since HIF-1a, the major transcription
factor of hypoxia-related genes involved in angiogenesis
and apoptosis, has been recently implicated in the patho-
genesis of fibrotic lung disease we sought to investigate
the expression of its inhibitor, ING4, both in mRNA and
protein level using qRT-PCR and immunohistochemistry
analysis, respectively, in a well characterized model of
pulmonary fibrosis. Surprisingly, following disease pro-
gression, ING4 expression was found downregulated,
both in mRNA and protein level, as shown in Figures 1
and 2. In particular, qRT-PCR analysis demonstrated that
Ing4 gene expression was downregulated upon adminis-
tration of BLM and the development of pulmonary
inflammation and fibrosis (Figure 1). Experimental find-
ings were further extended by immunohistochemistry
analysis for ING4 expression on lung paraffin sections
from BLM treated mice (7, 15 and 23 days post adminis-
tration) which confirmed decreased expression during
disease progression. ING4 was extensively expressed in
normal epithelium in control lung samples, as well as in
early stages of disease (day 7) where inflammation is
prominent and fibrosis is almost absent (Figure 2).
Decreased expression of ING4 within IPF lung compared 
to COP and control samples
Because BLM-model of pulmonary fibrosis is not fully
representative of IPF due to its self limiting nature, rapid-
ity of its development and close association between lung
injury and inflammation[22], we sought to extend our
observations in patients with IPF and COP, two different
types of pulmonary fibrosis with different disease progres-
siveness and treatment responsiveness. In accordance
with results showed in our experimental model of pulmo-
nary fibrosis, Ing4 gene expression was downregulated in
four available IPF compared to six controls and four COP
whole lung samples (Figure 3). The samples included in
this analysis were representative of a total number of 70
tissue samples (30 IPF, 20 controls and 20 COP) used for
TMA construction and immunohistochemistry semi-
quantitative analysis which further corroborated ING4
down-regulation in IPF patients compared to controls and
COP subjects, on a protein level as well (Figure 4). In par-
ticular, ING4 showed strong staining intensity within nor-
mal epithelium and endothelium, in almost 90% of
control lung samples whereas it was also visualized in
alveolar epithelial cells surrounding areas of active fibro-
sis, also known as Masson bodies, within the COP lung
(80% or 16/20 patients). No statistical difference in stain-
ing intensity was observed between COP and control lung
samples in ING4 expression (Figure 4). On the contrary,
ING4 was almost absent within IPF lung in the majority
of IPF patients (80%), including areas of active fibrosis,
also called fibroblastic foci, as well as alveolar epithelial
cells immediately adjacent to them (Figure 4).
ING4 semi-quantitative expression levels were negatively 
correlated with pulmonary function parameters in IPF 
patients
To strengthen the evidence that decreased ING4 expres-
sion may contribute to the progression of fibrosis we
sought to correlate ING4 semi-quantitative immunohisto-
Ing4 mRNA expression levels in BLM-induced pulmonary  fibrosis Figure 1
Ing4 mRNA expression levels in BLM-induced pulmo-
nary fibrosis. Ing4 gene expression levels quantified by qRT-
PCR showed a trend to increase, compared to control 
untreated mice, at early disease stages (day 7 post-adminis-
tration) whereas a gradual decline, compared to control and 
day 7 mice, following disease progression (days 7 and 15) was 
easily noted. All values were normalized with the reference 
gene B2m and presented as relative expression to the con-
trol sample as described in materials and methods. *p < 0.05, 
**p < 0.005, ***p < 0.001. (One way ANOVA).
Ing4 gene expression in BLM-induced PF
**Respiratory Research 2009, 10:14 http://respiratory-research.com/content/10/1/14
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Decreased ING4 expression in bleomycin (BLM)- induced pulmonary fibrosis (PF) following disease progression Figure 2
Decreased ING4 expression in bleomycin (BLM)- induced pulmonary fibrosis (PF) following disease progres-
sion. (A) Representative immunohistochemistry with an anti-ING4 antibody on lung paraffin sections from BLM-treated mice 
(7, 15, and 23, days post-administration). ING4 was mainly expressed in alveolar epithelium (days 7 and 15) whereas showed 
weak staining within areas of dense fibrosis and collagen deposition at late disease stages (day 21). (B) Computerized image 
analysis of immunostained sections. *p < 0.05, **p < 0.005, ***p < 0.001. (One way ANOVA and unpaired t-test with Bonfer-
roni correction, F = 71,126).
A 
x20       x40 
Saline   
d7
d15  
d23 
B 
Ing4
R
e
v
e
r
s
e
 
S
t
a
i
n
i
n
g
 
I
n
t
e
n
s
i
t
y
 
(
%
) 0
20
40
60
80
saline d7
***
*** = Pvalue 0.001
** = Pvalue 0.01
* = Pvalue 0.05
d15 d23
**
***
**Respiratory Research 2009, 10:14 http://respiratory-research.com/content/10/1/14
Page 6 of 10
(page number not for citation purposes)
chemistry expression levels with pulmonary function
parameters including forced vital capacity (FVC), total
lung capacity (TLC) and diffuse lung capacity as expressed
by KCO (carbon monoxide transfer coefficient), in IPF
patients. Most intriguingly statistical analysis clearly dem-
onstrated an almost linear negative relationship between
ING4 down-regulation and FVC (p < 0.001, correlation
coefficient = -0,933), TLC (p < 0.001, correlation coeffi-
cient = -0,984) and finally KCO (p < 0.001, correlation
coefficient = -0,951), as shown in Figure 5(A, B) and 5(C)
respectively.
Discussion
In the present study we analyzed, for the first time in the
literature, the expression profiles of ING4 in the experi-
mental model of pulmonary fibrosis as well as in patients
with two different forms of fibrotic lung disease, IPF and
COP. ING4 is a candidate tumor suppressor gene that
functions in cell proliferation, contact inhibition and ang-
iogenesis. Seminal observations have attributed ING4 a
beneficial role in regulating cancer invasion, migration
and metastasis and highlighted it as a novel therapeutic
target[23]. ING4 is widely expressed in normal cell lines
while it is down-regulated in glioblastoma[24] and
melanoma cells[23] as well as in head and neck squamous
cell carcinoma[25]. ING4 negatively regulates cell prolif-
eration leading to growth inhibition through its capability
to interact with p300 and consequently enhance p53
acetylation, promoting p53-dependent apoptosis[8].
The last fifteen years parallels have been drawn between
lung cancer and pulmonary fibrosis. The unremitting
recruitment and maintenance of the altered fibroblast
phenotype with generation of highly-proliferative immor-
tal fibroblasts[22,26,27] coupled with the epithelial-mes-
enchymal transition (EMT)[22,28-32] phenomenon is
reminiscent with the transformation of cancer cells and
metaplasia. Additionally, recently emerged evidence
implicating increased angiogenic activity and aberrant
vascular remodeling in the etiopathogenesis of pulmo-
nary fibrosis has attracted much atten-
tion[15,18,19,28,33,34]. However, despite intense
research efforts the pathogenetic cascade of fibrotic lung
disease still remains elusive and controversial. To this end
and in an attempt to scrutinize for novel disease media-
tors, our study group recently identified HIF-1a and other
hypoxia related genes as the most deregulated during dis-
ease progression in a well characterized animal model of
pulmonary fibrosis. Extending beyond target identifica-
tion, the role of HIF-1a signaling was further explored
with a series of experiments which revealed overexpres-
sion in the hyperplastic epithelium of IPF patients, colo-
calizing with its target genes, p53 and vascular endothelial
growth factor (VEGF), involved in apoptosis and angio-
genesis, respectively[15].
Following the above series of experiments and to shed fur-
ther light on the fibrogenic cascade, we sought to deter-
mine the expression profiles of ING4, also known as
inhibitor of HIF-1a, in different forms of pulmonary
fibrosis, including the experimental model and two types
of idiopathic fibrotic lung disease, IPF and COP. The lat-
ters, while belonging at the same disease group they
present with different clinical course and treatment
responsiveness that may be attributed to distinct apop-
totic and angiogenic profiles. Interestingly, we noticed a
significant down-regulation of ING4 expression, both in
mRNA and protein level, in the BLM-model of pulmonary
fibrosis compared to untreated mice. Intriguingly,
reduced expression of ING4 was noted as a gradual
decline in parallel with disease progression. As shown, in
figures 1 and 2, ING4 was widely expressed at early stages
of the disease (day 7) (a trend toward increased expres-
sion was noticed at this time point compared to control
untreated mice), whereas showed significant reduction as
disease was progressing from mild inflammation towards
dense fibrosis and areas of architectural distortion (day
21). This expression pattern is opposing to that seen for
HIF-1a, where a gradual increase following disease pro-
gression was demonstrated. On the basis of the anti-pro-
ING4 mRNA expression levels in patients with idiopathic pul- monary fibrosis (IPF), cryptogenic organizing pneumonia  (COP) and control (ctrl) subjects Figure 3
ING4 mRNA expression levels in patients with idio-
pathic pulmonary fibrosis (IPF), cryptogenic organiz-
ing pneumonia (COP) and control (ctrl) subjects. 
Significant reduction of ING4 gene expression levels in IPF 
patients compared to COP and control subjects, as quanti-
fied by qRT-PCR. Cycle threshold (Ct) values for each sam-
ple were converted to concentration values (through a 
standard curve of serial dilutions of a reference sample), nor-
malized to the corresponding values of the reference gene 
B2M and presented as expression index. *p < 0.05, **p < 
0.005, ***p < 0.001 (One way ANOVA).
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Decreased ING4 expression within IPF lung compared to COP and normal lung Figure 4
Decreased ING4 expression within IPF lung compared to COP and normal lung. (A) Representative immunohisto-
chemistry with an anti-ING4 antibody on lung paraffin sections from IPF and COP patients as well as control (CTRL) subjects. 
ING4 was extensively expressed in normal alveolar epithelial and endothelial cells in control lung samples and was also visual-
ized in alveolar epithelial cells surrounding areas of active fibrosis, called Masson bodies, within COP lung. On the contrary, 
ING4 was almost absent in alveolar epithelium and fibrotic interstitium (fibroblastic foci) within IPF lung. (B) Computerized 
image analysis of immunostained sections. *p < 0.05, **p < 0.005, ***p < 0.001 (One way ANOVA and unpaired t-test with 
Bonferroni correction, F = 171,126).
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Negative correlation between ING4 semi-quantitative expression levels and pulmonary function parameters in IPF patients Figure 5
Negative correlation between ING4 semi-quantitative expression levels and pulmonary function parameters 
in IPF patients. Spearman's correlation was performed and clearly demonstrated an almost linear negative association 
between ING4 down-regulation and parameters of disease progression including including forced vital capacity (FVC) (A), total 
lung capacity (TLC) (B) and diffuse lung capacity as expressed by KCO (carbon monoxide transfer coefficient) (C), in IPF 
patients.
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liferative, anti-angiogenic and anti-oncogenic properties
of ING4, one can easily suggest that the above expression
pattern (trend to increase as disease starts to develop and
significant decline as disease progresses) may represent a
protective compensatory response of the epithelium
against the injurious stimulus of BLM-administration.
Because BLM-model of pulmonary fibrosis is not fully
representative of IPF we sought to enhance our findings in
patients with IPF and COP. In line with animal results,
both mRNA and protein levels of ING4 were found down-
regulated in IPF compared to COP patients and normal
subjects. Our data are in accordance with findings in can-
cer cell lines and patients who exhibited dramatically
decreased ING4 levels which correlated with poorer sur-
vival and low treatment responsiveness. Most intrigu-
ingly, ING4 was almost absent within IPF lung while
showed only prominent staining in the alveolar epithe-
lium surrounding areas of active fibrosis, called Masson
bodies, within COP lung. Although speculative, it is rea-
sonable to assume that ING4 is reduced in more progres-
sive and irreversible forms of pulmonary fibrosis and its
suppression may abrogate its versatile protective proper-
ties contributing to rapid disease progression and poor
treatment responsiveness.
ING4 down-regulation may be explained both by genetic
and environmental factors. In particular, it has been pro-
posed that the reduction of ING4 expression in head and
neck squamous cell carcinoma as well as in glioblast-
oma[24] and melanoma[23,35] patients maybe attrib-
uted to mutations or deletions at chromosome 12p12-13,
which includes Ing4 gene. Whether patients with sporadic
or familial IPF present with mutations in Ing4, as it hap-
pens with telomerase [36-39], and whether these muta-
tions affect ING4 expression and are associated with
patients' survival and treatment response, remains to be
proven.
Finally, in an attempt to support our premise that ING4
downregulation may contribute to lung fibrosis and lead
to more progressive disease stages, we have demonstrated
that ING4 semi-quantitative expression levels are nega-
tively associated with markers of disease prognosis includ-
ing pulmonary function parameters such as FVC, TLC and
KCO, as shown in Figure 5(A, B) and 5(C) respectively. In
addition, this linear correlation may indicate ING4 as a
potential biomarker that could reliably predict clinical
course and treatment response in IPF patients. However,
future longitudinal studies in a large number of well
defined patients are sorely needed to support this provoc-
ative hypothesis.
Despite relative enthusiasm arising from the above obser-
vations, our data exhibit a number of limitations that
should be treated with caution. Firstly, based on our find-
ings, it is rather unclear whether ING4 down-regulation
within fibrotic lung is a primary event or just a conse-
quence of the fibrogenic cascade. However, in order for a
causal-effect relationship to be proven, generation of
ING4 knockout and/or transgenic mice is sorely needed.
Secondly, based on our approach it is not definitive
whether ING4 inactivation leads to abrogation of these
protective (anti-migratory, anti-angiogenic) properties
and is partially responsible for poor patients' survival.
Nevertheless, our study represents the first attempt to
implicate a novel tumor-suppressor protein in the patho-
genesis of pulmonary fibrosis and to associate its rela-
tively obvious absence with disease development and
progression.
Collectively our dataset demonstrates for the first time in
the literature down-regulation of ING4 in different forms
of pulmonary fibrosis. Reduced expression of ING4 may
facilitate aberrant vascular remodelling and fibroblast
proliferation and migration leading to progressive disease
and culminating to a fatal outcome. Our observations
suggest that ING4 may serve as a reliable prognosticator as
well as a potential therapeutic target for a group of dis-
eases with unfavourable prognosis and yet ineffective
treatment. Future prospective studies in patients with dif-
ferent types of fibrotic lung disease searching for Ing4
mutations coupled with experimental data using ING4
knockout mice may provide a way forward.
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